SCHEMBL969760

SCHEMBL969760

COc1cc2nc(C)c3c(C)nc(-c4ccccc4Cl)n3c2cc1Cl

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 20/20 0.59
PDE10A Q9Y233 20/20 0.59
PDE6D O43924 4/20 0.51
PDE6A P16499 4/20 0.51
PDE6G P18545 4/20 0.51
PDE6B P35913 4/20 0.51
PDE6C P51160 4/20 0.51
PDE6H Q13956 4/20 0.51
PDE4A P27815 4/20 0.51
PDE4B Q07343 3/20 0.51
PDE4C Q08493 3/20 0.51
PDE4D Q08499 3/20 0.51
PDE3B Q13370 1/20 0.46
PDE3A Q14432 1/20 0.46
PDE7A Q13946 2/20 0.46
PDE5A O76074 2/20 0.45
PDE11A Q9HCR9 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL970857 0.92 PDE10A (0.58) PDE2APDE10APDE6DPDE6APDE6G
SCHEMBL970300 0.87 PDE10A (0.61) PDE2APDE10APDE6DPDE6APDE6G
SCHEMBL971396 0.83 PDE2A (0.71) PDE2APDE10APDE6DPDE6APDE6G
SCHEMBL969498 0.81 PDE10A (0.67) PDE2APDE10APDE6DPDE6APDE6G
SCHEMBL971403 0.81 PDE10A (0.67) PDE2APDE10APDE6DPDE6APDE6G
SCHEMBL968986 0.80 PDE2A (0.69) PDE2APDE10APDE7A
SCHEMBL969103 0.79 PDE10A (0.61) PDE2APDE10APDE7APDE5APDE11A
SCHEMBL972494 0.79 PDE10A (0.72) PDE2APDE10APDE6DPDE6APDE6G
SCHEMBL971176 0.78 PDE10A (0.79) PDE2APDE10APDE6DPDE6APDE6G
SCHEMBL972787 0.78 PDE2A (0.77) PDE2APDE10APDE7A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7875618-B2 8-chloro-3,4-dimethyl-1-(2- methylphenyl)imidazo[1,5- a]quinoxaline; inhibitors of phosphodiesterase 10; for treatment of central nervous system disorders (cognitive deficits, social phobia, reduced vigilance, obesity and psychosis) WYETH (US) 2011-01-25 US claimed
EP-2225248-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-A]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 Wyeth LLC (US) 2010-09-08 EP claimed
WO-2009070584-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-A]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 WYETH (US) 2009-06-04 WO claimed
US-20090143367-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-a]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 ELBION GMBH (DE) 2009-06-04 US claimed
US-7875618-B2 8-chloro-3,4-dimethyl-1-(2- methylphenyl)imidazo[1,5- a]quinoxaline; inhibitors of phosphodiesterase 10; for treatment of central nervous system disorders (cognitive deficits, social phobia, reduced vigilance, obesity and psychosis) WYETH (US) 2011-01-25 US disclosed
US-20090143367-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-a]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 ELBION GMBH (DE) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143367-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-a]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 PDE12, PDE5A, PDE10A PDE2A 6/4885PDE10A 3/4885PDE6D 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.